Get started
Author

Andrew Garrison

Observed names: A. Garrison, Andrew J. Garrison
OpenAlex ID: A5043545646
Little Cigars are More Toxic than Cigarettes and Uniquely Change the Airway Gene and Protein Expression
2017 · Arunava Ghosh, Sabri H. Abdelwahab, et al. · Scientific Reports · 34
PDF
Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
2025 · Gerd R Burmester, Eduardo Mysler, et al. · RMD Open · 6
PDF
S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
2023 · Marla C. Dubinsky, Geert D'Haens, et al. · The American Journal of Gastroenterology · 1
Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies
2026 · Minhu Chen, Xiang Gao, et al. · Journal of Gastroenterology
PDF
Su1637 DURABLE EFFICACY OF RISANKIZUMAB THROUGH WEEK 148 IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: A POST HOC ANALYSIS OF PART 2 OF THE SEQUENCE STUDY
2026 · Raja Atreya, James O. Lindsay, et al. · Gastroenterology
Tu1644 LONG-TERM EFFICACY OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE AND PRIOR BIOLOGIC USE
2026 · Raja Atreya, Remo Panaccione, et al. · Gastrointestinal Endoscopy
Tu1644 LONG-TERM EFFICACY OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE AND PRIOR BIOLOGIC USE
2026 · Raja Atreya, Remo Panaccione, et al. · Gastroenterology
Su1637 DURABLE EFFICACY OF RISANKIZUMAB THROUGH WEEK 148 IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: A POST HOC ANALYSIS OF PART 2 OF THE SEQUENCE STUDY
2026 · Raja Atreya, James O. Lindsay, et al. · Gastrointestinal Endoscopy
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies
2026 · Peter C Taylor, Arthur Kavanaugh, et al. · RMD Open
PDF
46 Association Between Induction Response and Maintenance Dosing: A Post-Hoc Analysis of Upadacitinib-Treated Patients With Crohn’s Disease and Ulcerative Colitis
2025 · Bruno Silva, Maithili Chitnavis, et al. · The American Journal of Gastroenterology
S7 Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn’s Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
2023 · Edward Loftus, Miguel Regueiro, et al. · The American Journal of Gastroenterology
S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
2023 · David T. Rubin, Edward V. Loftus, et al. · The American Journal of Gastroenterology
Tu1709 CORTICOSTEROID DISCONTINUATION AND CLINICAL OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH UPADACITINIB
2023 · Marla C. Dubinsky, Geert D'Haens, et al. · Gastroenterology
Effet de l’upadacitinib, de l’adalimumab et d’un placebo sur la douleur résiduelle chez des patients atteints de polyarthrite rhumatoïde dont l’inflammation s’est atténuée après trois et six mois de traitement
2022 · L. Bessette, A.M. Kakehasi, et al. · Revue du Rhumatisme
Works count: 14
Citation count: 41
H-index: 2
I10-index: 1
Year
Topic
Type